WMT

120.8

+1.54%↑

COST

966.71

-0.51%↓

PG

144.02

-0.41%↓

KO

75.18

+0.55%↑

PM

163.47

+0.29%↑

WMT

120.8

+1.54%↑

COST

966.71

-0.51%↓

PG

144.02

-0.41%↓

KO

75.18

+0.55%↑

PM

163.47

+0.29%↑

WMT

120.8

+1.54%↑

COST

966.71

-0.51%↓

PG

144.02

-0.41%↓

KO

75.18

+0.55%↑

PM

163.47

+0.29%↑

WMT

120.8

+1.54%↑

COST

966.71

-0.51%↓

PG

144.02

-0.41%↓

KO

75.18

+0.55%↑

PM

163.47

+0.29%↑

WMT

120.8

+1.54%↑

COST

966.71

-0.51%↓

PG

144.02

-0.41%↓

KO

75.18

+0.55%↑

PM

163.47

+0.29%↑

Search

Afya Ltd (Class A)

Cerrado

SectorConsumo defensivo

15.11 4.28

Resumen

Variación precio

24h

Actual

Mínimo

14.74

Máximo

15.19

Métricas clave

By Trading Economics

Ingresos

-5M

176M

Ventas

-1.6M

927M

P/B

Media del Sector

9.108

28.772

Rentabilidad por dividendo

4.64

Margen de beneficios

18.945

EBITDA

-120M

277M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 Meses

+19.81% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

4.64%

3.67%

Próximas Ganancias

7 may 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

26M

1.3B

Apertura anterior

10.83

Cierre anterior

15.11

Noticias sobre sentimiento de mercado

By Acuity

100%

0%

124 / 131 Clasificación en Consumer defensive

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

Afya Ltd (Class A) Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

23 mar 2026, 23:47 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23 mar 2026, 22:55 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23 mar 2026, 21:51 UTC

Adquisiciones, fusiones, absorciones

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23 mar 2026, 23:59 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

23 mar 2026, 23:59 UTC

Charlas de Mercado

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23 mar 2026, 23:50 UTC

Charlas de Mercado

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23 mar 2026, 23:37 UTC

Charlas de Mercado

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23 mar 2026, 22:42 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Global Equities Roundup: Market Talk

23 mar 2026, 22:42 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23 mar 2026, 22:40 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23 mar 2026, 22:23 UTC

Charlas de Mercado

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23 mar 2026, 22:22 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23 mar 2026, 22:21 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23 mar 2026, 22:21 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23 mar 2026, 22:20 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23 mar 2026, 22:20 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23 mar 2026, 22:19 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23 mar 2026, 22:19 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23 mar 2026, 22:18 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23 mar 2026, 22:15 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23 mar 2026, 22:08 UTC

Charlas de Mercado

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23 mar 2026, 21:42 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

23 mar 2026, 21:42 UTC

Charlas de Mercado

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23 mar 2026, 21:32 UTC

Ganancias

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23 mar 2026, 21:32 UTC

Ganancias

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23 mar 2026, 21:32 UTC

Ganancias

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23 mar 2026, 21:10 UTC

Noticias de Eventos Importantes

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23 mar 2026, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

23 mar 2026, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

23 mar 2026, 20:50 UTC

Charlas de Mercado
Ganancias
Noticias de Eventos Importantes

Basic Materials Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Afya Ltd (Class A) previsión

Precio Objetivo

By TipRanks

19.81% repunte

Estimación a 12 Meses

Media 17.6 USD  19.81%

Máximo 22 USD

Mínimo 16 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Afya Ltd (Class A) Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

5 ratings

0

Comprar

4

Mantener

1

Vender

Puntuación técnica

By Trading Central

18.968 / 19.56Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Strong Bullish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Afya Ltd (Class A)

Afya Limited operates as a medical education group in Brazil. The company operates through three segments: Undergrad, Continuing Education, and Digital Services. It offers educational products and services, including medical schools, medical residency preparatory courses, graduate courses, and other programs to lifelong medical learners enrolled across its distribution network, as well as to third-party medical schools. The company provides digital health services, such as subscription-based mobile app and website portal that focuses on assisting health professionals and students with clinical decision-making through tools, such as medical calculators, charts, and updated content, as well as prescriptions, clinical scores, medical procedures and laboratory exams, and others. It offers health sciences courses, which comprise medicine, dentistry, nursing, radiology, psychology, pharmacy, physical education, physiotherapy, nutrition, and biomedicine; and degree programs and courses in other subjects and disciplines, including undergraduate and post graduate courses in business administration, accounting, law, civil engineering, industrial engineering, and pedagogy. In addition, the company provides medical postgraduate specialization programs; printed and digital content; and an online medical education platform and practical medical training services. Further, it offers iClinic, a practice management software; educational health and medical imaging solutions through an interactive platform; Cliquefarma, a free-to-use website that tracks prescription drugs, cosmetics and personal hygiene product prices; Shosp, a clinical management software; RX PRO, a solution that connects physicians with the pharmaceutical industry; and Glic, a free diabetes care and management app solution for physicians and patients. The company was founded in 1999 and is headquartered in Nova Lima, Brazil.
help-icon Live chat